Daxor Corporation begins trading on the NASDAQ Capital Market


Management will ring the Nasdaq stock market opening bell on February 4, 2022

Oak Ridge, Tenn., Feb. 02, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that it has commenced trading on the NASDAQ Capital Markets effective today, February 2, 2022, and that she will visit the Nasdaq MarketSite in Times Square on Friday, February 4, 2022 In honor of the occasion, Michael Feldschuh, CEO and Chairman will ring the opening bell.

“We are excited to begin trading on NASDAQ Capital Markets today and believe this step better positions Daxor to capitalize on Nasdaq’s long tradition of listing category-defining medical technology companies. This fits well with Daxor’s innovative portfolio of blood volume technologies,” commented Michael Feldschuh, CEO and President of Daxor. “This move will improve the visibility of our shares, improve the liquidity of our shares and provide us with greater exposure to institutional investors.”

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

Friday, February 4, 2022 – 9:15 a.m. to 9:30 a.m. ET

Daxor media contact:
Linda Dyson

[email protected]

Nasdaq MarketSite Media Contact:
Pierre Gau
(201) 388-9682

[email protected]

Stream Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
Lower 18MHz
DL 3811 vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0

Social Media:
For media features such as exclusive content, photo posts, status updates and bell ceremony videos, please visit our Facebook page:


For ceremony and event photos, please visit our Instagram page:


For news tweets, please visit our Twitter page:


A live stream of the Nasdaq opening bell will be available on:


For a high resolution photo of the Market Open, go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony and click on the open market of your choice.

On Daxor company

Daxor Corporation (Nasdaq: DXR) is the world leader in blood volume measurement technology focused on innovation in blood volume testing. We developed and marketed the BVA-100® (Blood Volume Analyzer), the first FDA-cleared diagnostic blood test to provide safe, accurate, and objective quantification of blood volume status and composition against standards patient specific. More than 60,000 tests have been performed at major hospitals across the United States, improving hospital performance measures across a wide range of surgical and medical conditions, including dramatically reducing heart failure mortality and readmissions and intensive care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with NIH support and is developing analyzers under contract to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management through blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

Forward-looking statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the impact of the hiring of sales personnel and the expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this release, including, without limitation, the risks associated with our post-marketing clinical data collection activities, the benefits of our products for patients, our expectations of product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection , FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other additional risks and uncertainties described in our SEC filings. Forward-looking statements speak only as of the date they are made. Daxor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact with Investor Relations:
Bret Shapiro
Senior Managing Partner, CORE IR

[email protected]

main logo


Comments are closed.